
HOLYPHARM
In recent years, GLP-1 receptor agonists have gained significant attention in diabetes and weight management. Among them, semaglutide stands out not only for its excellent glycemic and weight control but also for its emerging role in chronic kidney disease (CKD) management. The FLOW study, presented at the 2024 ERA (European Renal Association) Congress, provided the first high-quality randomized controlled trial evidence of semaglutide’s renoprotective effects, marking a breakthrough in the treatment of CKD.
The FLOW trial enrolled over 3,500 patients with type 2 diabetes and various stages of CKD. Participants were randomized to receive weekly 1.0 mg semaglutide or placebo, with a median follow-up of 3.4 years. The results showed a significant 24% reduction in the risk of kidney disease progression, and a slower rate of eGFR decline. Notably, the risk of major kidney outcomes such as end-stage kidney disease or renal death was significantly lower in the semaglutide group.
Mechanistically, semaglutide reduces glomerular pressure via improved glycemic control and weight loss. It also has anti-inflammatory and antifibrotic properties and improves endothelial function, all of which contribute to kidney protection.
The drug demonstrated consistent benefits across different CKD stages, with a favorable safety profile. This supports its inclusion, alongside SGLT2 inhibitors and ACE inhibitors, as a recommended treatment in patients with diabetes and CKD.
Future studies are expected to explore its use in non-diabetic kidney disease and in combination with other renoprotective agents. Semaglutide is set to become a new pillar in the integrated management of chronic kidney disease.